The 2021 international working group consensus report Redefining outcomes in immune TTP updated response and relapse terminology to better reflect ADAMTS13 activity and the effects of anti-VWF therapy.
The publication distinguishes clinical remission and relapse from ADAMTS13 remission and relapse, and updates the way exacerbation and remission are benchmarked as treatment pathways evolve.